TESAMORELIN | 10 MG

Tesamorelin is a synthetic 44-amino-acid peptide analog of growth hormone-releasing hormone (GHRH), modified for enhanced stability and potency. It acts as a growth hormone secretagogue, binding to GHRH receptors in the pituitary gland to stimulate the natural, pulsatile release of endogenous growth hormone (GH), which in turn elevates IGF-1 levels and supports metabolic and anabolic processes.

Tesamorelin is FDA-approved (under brands like Egrifta SV and the newer Egrifta WR formulation) specifically for reducing excess visceral abdominal fat (lipodystrophy) in adults with HIV, but it has drawn research interest for broader metabolic and body composition applications.

Potential human benefits (supported by robust clinical trials in HIV populations, including reductions in visceral adipose tissue (VAT), improvements in fat quality, and emerging data on muscle and liver effects, plus anecdotal reports in wellness and anti-aging contexts):

• Targeted visceral fat reduction — consistently decreases deep abdominal (visceral) fat by 15–20% or more over 26–52 weeks in studies, leading to improved waist circumference and body contouring without general weight loss intent.
• Improved fat quality and distribution — increases density of visceral and subcutaneous fat (indicating healthier fat composition), reduces liver fat (e.g., in NAFLD models), and decreases intramuscular fat while preserving or increasing lean muscle area/density in truncal muscles.
• Better body composition and muscle support — promotes lean mass gains, enhanced muscle area (e.g., rectus, psoas), and overall metabolic improvements like favorable lipid profiles (lower triglycerides, better cholesterol ratios).
• Metabolic and cardiometabolic perks — hints of better insulin sensitivity, glucose handling, and reduced inflammation markers; supports energy expenditure and resilience against metabolic stress.
• General vitality and recovery — anecdotal accounts often highlight increased energy, better recovery from physical demands, and a sense of rejuvenation tied to elevated GH/IGF-1 signaling.

Human evidence is strongest from multiple randomized, placebo-controlled trials (e.g., pivotal studies showing consistent VAT reductions, lipid improvements, and no major worsening of glucose tolerance), with ongoing research exploring adjunctive use with exercise for physical function in HIV and potential in non-HIV metabolic conditions. Benefits are dose-dependent (typically 1–2 mg daily subcutaneous injection) and most effective with lifestyle support.

Important Notice:

This product is intended for research use only.
Not for human or animal use of any kind.
Not a drug. Not approved for clinical or therapeutic use.

This product is intended for research use only.
Not for human or animal use of any kind.
Not a drug. Not approved for clinical or therapeutic use.